-

SPECTRUM PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Spectrum Pharmaceuticals, Inc. - SPPI

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI).

On August 6, 2021, the Company disclosed the receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the application for its drug candidate, ROLONTIS, that highlighted manufacturing deficiencies and indicated that a reinspection of the Company’s manufacturing facility would be necessary.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.

KSF’s investigation is focusing on whether Spectrum’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Spectrum shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-sppi/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Kahn Swick & Foti, LLC

NASDAQ:SPPI

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

Futu Holdings 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Futu Holdings Limited - FUTU

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2026 to file lead plaintiff applications in a securities class action lawsuit against Futu Holdings Limited ("Futu" or the "Company") (NasdaqGM: FUTU), if they purchased or otherwise acquired the Company’s securities between May 24, 2023 and May 27, 2026, inclusive (the “Class Period”). This...

Weave Communications Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Weave Communications, Inc. - WEAV

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Weave Communications, Inc. (NYSE: WEAV) to Francisco Partners. Under the terms of the proposed transaction, shareholders of Weave will receive $7.40 in cash for each share of Weave that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,...

Translational Development Investor Alert: Kahn Swick & Foti, LLC Investigates Translational Development Acquisition Corp. - TDAC

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Translational Development Acquisition Corp. (the “Company”) (NasdaqGM: TDAC) and Prologium Holding Inc. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Translational shareholders. If you would like to discuss your le...
Back to Newsroom